Cellebrite DI (CLBT) vs monday.com (MNDY)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
Cellebrite DI (CLBT) has outperformed monday.com (MNDY) over the past year, losing 36.2% versus a loss of 50.9%. Over five years, CLBT leads with a +24.1% price change compared with -78.7% for MNDY. monday.com is the larger company by market cap ($3.05 billion vs $2.71 billion), about 1.1 times the size.
On valuation, monday.com trades at a lower forward P/E (9.7x vs 16.1x for Cellebrite DI). Cellebrite DI converts more of its revenue into profit, with a net margin of 16.5% versus 9.6%.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | CLBT | MNDY |
|---|---|---|
| Share price | $10.77 | $72.16 |
| Market cap | $2.71B | $3.05B |
| 1-day change | -4.86% | +3.23% |
| YTD return | -40.27% | -51.10% |
| 1-year return | -36.20% | -50.86% |
| 5-year return | +24.08% | -78.74% |
| P/E ratio (TTM) | 43.08 | 24.80 |
| Forward P/E | 16.09 | 9.65 |
| EPS (TTM) | $0.25 | $2.91 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Revenue (latest FY) | $475.68M | $1.23B |
| Revenue growth (YoY) | +18.56% | +26.75% |
| Net income (latest FY) | $78.33M | $118.74M |
| Gross margin | 84.20% | 89.20% |
| Operating margin | 13.98% | -0.14% |
| Net margin | 16.47% | 9.64% |
| 52-week high | $19.39 | $164.49 |
| 52-week low | $9.58 | $57.50 |
| Distance from 52-week high | -44.46% | -56.13% |
| Analyst consensus | strong_buy | buy |
| Avg. price target upside | +43.27% | +39.87% |
| Average volume | 2.35M | 1.14M |
| Shares outstanding | 251.34M | 42.27M |
| Employees | 1,285 | 3,155 |
| Sector | Technology | Technology |
| Industry | Computer Software: Prepackaged Software | Computer Software: Prepackaged Software |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CLBT has outperformed MNDY by 14.7 percentage points over the past year.
- Cellebrite DI trades at a higher earnings multiple (43.1x vs 24.8x trailing P/E).
- Cellebrite DI is more profitable, keeping 16.5 cents of every revenue dollar as net income versus 9.6 cents for monday.com.
- monday.com grew revenue faster in its latest fiscal year (+26.75% vs +18.56%).
About Cellebrite DI
CLBT stock →Cellebrite DI Ltd. develops software and services for legally sanctioned investigations in Europe, the Middle East, Africa, the Americas, and the Asia-Pacific.
Technology · Computer Software: Prepackaged Software · 1,285 employees
About monday.com
MNDY stock →monday.com Ltd., together with its subsidiaries, develops software applications in the United States, Europe, the Middle East, Africa, the United Kingdom, and internationally. The company provides Work Operating System (Work OS), a cloud-based visual work OS that consists of modular building blocks used and assembled to create software applications and work management tools.
Technology · Computer Software: Prepackaged Software · 3,155 employees
CLBT vs MNDY FAQ
Which is bigger, Cellebrite DI or monday.com?
monday.com (MNDY) is larger, with a market capitalization of $3.05B compared with $2.71B for Cellebrite DI (CLBT).
Which stock has performed better over the past year, CLBT or MNDY?
CLBT returned -36.20% over the past 12 months, compared with -50.86% for MNDY (price return, excluding dividends). Past performance does not predict future results.
Which has the lower P/E ratio, CLBT or MNDY?
MNDY has the lower trailing P/E at 24.8, versus 43.1 for CLBT. A lower P/E is not by itself a sign of a better investment; it can reflect slower expected growth or higher risk.
Are Cellebrite DI and monday.com in the same industry?
Yes. Both are classified in the Computer Software: Prepackaged Software industry within the Technology sector.